K Hospital and Roche Pharma Vietnam co-organise cancer immunotherapy seminar

On June 25, the event brought together over 100 healthcare professionals to discuss effective treatment solutions for unresectable hepatocellular carcinoma (uHCC) and lung cancer.

Vietnam has witnessed a significant surge in the burden of cancer, with lung cancer and hepatocellular carcinoma being major concerns. The joint conference served as a platform for healthcare professionals to exchange knowledge, insights, and experiences regarding the latest advancements in cancer immunotherapy treatments.

Vietnam observed 182,563 new cancer cases in 2020. According to Globocan 2020, the number of new cases of liver cancer stood at 26,418 and lung cancer accounted for 26,262.

Dr. Do Anh Tu, deputy director of K Hospital, emphasised the significance of such conferences, "With the increasing burden of lung cancer and hepatocellular carcinoma in our country, it is crucial that we unite as healthcare professionals to share knowledge and expertise. This conference provides a unique platform for us to collectively work towards improving patient outcomes and advancing cancer care in Vietnam."

Immunotherapy and personalised treatment in the management of uHCC and lung cancer were a focus at the conference, with many promising results that could bring hope to patients. Research findings have demonstrated that immunotherapy helped to reduce the risk of death for advanced HCC by 42 per cent compared with standard care.

Lennor Carrillo, general director of Roche Pharma Vietnam, expressed his enthusiasm about the joint conference, "As a global leader in healthcare, Roche is dedicated to collaborating with partners to enhance the lives of patients and promote better health outcomes at a lower cost to society."

"We are privileged to join forces with K hospital in organising this impactful scientific conference, firmly believing that the exchange of valuable experience and effective treatments shared through this forum will significantly contribute to improving the overall outcomes for cancer patients. Together, we can make a meaningful difference in advancing cancer care and transforming the lives of those affected by this disease," concluded Carrillo.

The joint conference on cancer immunotherapy therapies by Roche Pharma Vietnam and K Hospital served as a testament to their commitment to addressing the rise of cancer in Vietnam.

By fostering collaboration, sharing expertise, and exploring innovative treatment solutions, the event is expected to pave the way for improved patient care and better outcomes for individuals battling uHCC and lung cancer.

DKSH, Roche extend partnership in Vietnam DKSH Business Unit Healthcare, a market expansion services provider for companies seeking to grow their healthcare business, in June signed an extended agreement with Roche Vietnam to strengthen its business growth.

Roche Vietnam and Ho Chi Minh City Oncological Hospital continue to improve cancer diagnosis and treatment capacity in Vietnam On March 25, Roche Pharma Vietnam and the Ho Chi Minh City Oncological Hospital (UB) signed an MoU to improve the professional capacity of the medical staff at the hospital and strengthen cooperation with domestic and foreign oncology organisations and experts for the benefit of patients and the community.

Roche Vietnam and Medical Service Administration sign MoU for liver cancer programme On May 10, Roche Vietnam and the Medical Service Administration – under the Ministry of Health – signed an MoU to conduct a joint liver cancer management programme in 2022-2023.